Sign Up Today and Learn More About ILiAD Biotechnologies Stock
Invest in or calculate the value of your shares in ILiAD Biotechnologies or other pre-IPO companies through EquityZen's platform.
ILiAD Biotechnologies Stock
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
About ILiAD Biotechnologies Stock
Founded
2012
Headquarters
New York, NY, US
Industries
Software, Artificial Intelligence, Data and Analytics
ILiAD Biotechnologies Press Mentions
Stay in the know about the latest news on ILiAD Biotechnologies
ILiAD bags $115m for pertussis vaccine, and other financings
pharmaphorum • Feb 14, 2026
ILiAD Biotechnologies of Weston raises $115M to advance whooping cough vaccine
refreshmiami • Feb 12, 2026
ILiAD banks $115m to take vaccine into pivotal study
thepharmaletter • Feb 12, 2026
ILiAD Biotechnologies Raises $115M in Series B Funding
finsmes • Feb 11, 2026
ILiAD Biotechnologies: $115 Million Series B Closed To Advance Intranasal Pertussis Vaccine
pulse2 • Feb 11, 2026
ILiAD Biotechnologies Management
Leadership team at ILiAD Biotechnologies
Founder and CEO
Keith Rubin
Board Member
Keith Rubin
Join now and verify your accreditation status to gain access to:
- ILiAD Biotechnologies Current Valuation
- ILiAD Biotechnologies Stock Price
- ILiAD Biotechnologies Management
- Available deals in ILiAD Biotechnologies and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- ILiAD Biotechnologies Cap Table and Funding History by Share Class and Liquidity Preferences
- ILiAD Biotechnologies Revenue and Financials
- ILiAD Biotechnologies Highlights
- ILiAD Biotechnologies Business Model
- ILiAD Biotechnologies Risk Factors
- ILiAD Biotechnologies Research Report from SACRA Research
Trading ILiAD Biotechnologies Stock
How to invest in ILiAD Biotechnologies stock?
Accredited investors can buy pre-IPO stock in companies like ILiAD Biotechnologies through EquityZen funds. These investments are made available by existing ILiAD Biotechnologies shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell ILiAD Biotechnologies stock?
Shareholders can sell their ILiAD Biotechnologies stock through EquityZen's private company marketplace. EquityZen's network includes over 420K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."